为了改善由组织胺(Hi)增多所致的病理变化,临床上常采用Hi受体阻断剂、Hi游离抑制剂和脱敏疗法,但始终未能获满意疗效。最近,出现了一种新的有效治疗手段,可选择性抑制Hi合成,减少Hi含量。组氨酸脱羧酶(HDC)是体内唯一参与Hi生物合成的酶,广泛存在于组织中,目前已知某些化合物可抑制其活性,其中较为重要的 In order to improve the pathological changes caused by the increase of histamine (Hi), Hi receptor blockers, Hi free inhibitors and desensitization therapy are often used clinically. However, no satisfactory curative effect has been achieved. Recently, a new and effective treatment has emerged that selectively inhibits Hi synthesis and reduces Hi content. Histidine decarboxylase (HDC) is the only enzyme involved in Hi biosynthesis in the body and is widely found in tissues. It is known that certain compounds inhibit the activity of histidine, of which the more important